The passing of world leading legislation on new psychoactive substances takes New Zealand a big step closer to healthy drug law, the New Zealand Drug Foundation said today.
“The Psychoactive Substances Act is a world first at getting ahead of the ‘legal highs’ industry and taking control of the problems these substances cause,” New Zealand Drug Foundation Executive Director Ross Bell said.
The law, which passed its final reading in Parliament today, sets up a regulatory framework where manufacturers of products like synthetic cannabis will have to prove they are ‘low risk’ before the can be sold. It also imposes restrictions on who can make and sell the substances as well as measures to reduce availability.
“This is a cutting edge and pragmatic approach to new psychoactive substances which will reduce the harm they cause in our communities,” Mr Bell said.
“It is fantastic that the Government has listened to community concerns, acted on the evidence and built consensus on the best way to handle this complicated area of policy.”
Mr Bell said that the regulation of new psychoactive substances was the first step in the right direction for healthy drug law.
“New Zealand now needs to implement broader health-focussed changes to our outdated drug laws.”
12 January 2021
KnowYourStuffNZ figures: People are choosing not to take the harmful cathinone eutylone, after discovering they had unwittingly purchased it...
17 December 2020
Drug law reform got majority support in several US states, and is heading off in new directions. Russell Brown pulled this summary together
17 December 2020
Newly appointed Executive Director Sarah provides some insight and hope as we near the end of 2020.
09 December 2020
The Drug Foundation's annual State of the Nation report highlights increasing demand for treatment and impacts of 2019 law change.
Back to top